Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

Extended ALPINE Follow-Up Confirms Zanubrutinib PFS Superiority

From the 65th American Society of Hematology Annual Meeting:
Patients given zanubrutinib for relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma continue to have better PFS than their ibrutinib-treated counterparts after 3 years

More news articles

OncologyPRO Alert

Receive a summary of latest published content every two weeks.


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.